Telik
Telik was a Palo Alto biotech whose glutathione analogue canfosfamide (Telcyta) failed its phase 3 trials in ovarian and lung cancer in the 2000s, a reminder that late-stage failure is the norm in oncology.
Overview
Telik, Inc., founded in 1988 in Palo Alto, California, developed canfosfamide (TLK286, Telcyta), a prodrug activated by glutathione S-transferase P1-1 that is overexpressed in many tumours. It led phase 3 trials in platinum-resistant ovarian cancer and non-small cell lung cancer, none of which met their primary endpoints, and the company later wound down its programmes. Its trials remain on ClinicalTrials.gov under Telik as lead sponsor.
Similar pages
not linked directly; found by shared links- CompanyAgennix
Shares Pivotal (registrational) trial, Clinical trial, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyIntra-IMMUSG
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyLee's Pharmaceutical
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyNobelpharma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.